ONCAlert | 2018 Gastrointestinal Cancers Symposium

Prostate Cancer MORE >>

Based on results of the phase III SPARTAN trial, apalutamide has been approved by the FDA for the treatment of patients with nonmetastatic castration-resistant prostate cancer, making it the first treatment to be approved in this setting.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.